Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Troy A. Shahoumian"'
Autor:
Valerie A. Smith, Theodore S. Z. Berkowitz, Paul Hebert, Edwin S. Wong, Meike Niederhausen, John A. Pura, Kristin Berry, Pamela Green, Anna Korpak, Alexandra Fox, Aaron Baraff, Alex Hickok, Troy A Shahoumian, Amy S.B. Bohnert, Denise M. Hynes, Edward J. Boyko, George N. Ioannou, Theodore J. Iwashyna, C. Barrett Bowling, Ann M. O’Hare, Matthew L. Maciejewski
Publikováno v:
BMC Medical Research Methodology, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Understanding how SARS-CoV-2 infection impacts long-term patient outcomes requires identification of comparable persons with and without infection. We report the design and implementation of a matching strategy employed by the Dep
Externí odkaz:
https://doaj.org/article/7052fc5a69ae46c8b4d1d2305b04c75b
Autor:
Valerie A. Smith, Theodore S. Z. Berkowitz, Paul Hebert, Edwin S. Wong, Meike Niederhausen, John A. Pura, Kristin Berry, Pamela Green, Anna Korpak, Alexandra Fox, Aaron Baraff, Alex Hickok, Troy A Shahoumian, Amy S.B. Bohnert, Denise M. Hynes, Edward J. Boyko, George N. Ioannou, Theodore J. Iwashyna, C. Barrett Bowling, Ann M. O’Hare, Matthew L. Maciejewski
Publikováno v:
BMC Medical Research Methodology, Vol 23, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/92436197f53e4e1296377a7fa53c8339
Autor:
Jacqueline M. Ferguson, Chantele Mitchell-Miland, Troy A. Shahoumian, Ernest Moy, Kenneth T. Jones, Alicia J. Cohen, Leslie R.M. Hausmann
Publikováno v:
Annals of Epidemiology. 73:22-29
Marginalized communities have been disproportionally impacted by SARS-CoV-2. How the associations between social determinants of health and the risk of SARS-CoV-2 infection shifted across time is unknown. In this evaluation, we examine individual-lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161301f05d9f2438d1658409fda64330
https://doi.org/10.1016/j.annepidem.2022.06.004
https://doi.org/10.1016/j.annepidem.2022.06.004
Publikováno v:
Hepatology. 66:27-36
Reactivation of hepatitis B virus (HBV) has been reported in hepatitis C virus–infected individuals receiving direct-acting antiviral (DAA) therapy. The overall risk among patients with current or prior HBV infection in the context of DAA treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::849c87250faf832ed78d4e85f86c7da7
https://doi.org/10.1002/hep.29135
https://doi.org/10.1002/hep.29135
Autor:
Troy A. Shahoumian, Larry A. Mole, Lisa I. Backus, Debika Bhattacharya, Timothy P. Loomis, Pamela S. Belperio, Matthew Bidwell Goetz
Publikováno v:
Clinical Infectious Diseases. 64:1711-1720
Author(s): Bhattacharya, Debika; Belperio, Pamela S; Shahoumian, Troy A; Loomis, Timothy P; Goetz, Matthew B; Mole, Larry A; Backus, Lisa I | Abstract: Background.Large cohorts are needed to assess human immunodeficiency virus (HIV)/hepatitis C virus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17621b8c6d5514b58f10d077b362b6b5
https://doi.org/10.1093/cid/cix111
https://doi.org/10.1093/cid/cix111
Autor:
Lisa I. Backus, Pamela S. Belperio, Mark Holodniy, Troy A. Shahoumian, Mark A. Winters, Thomas R. O'Brien, Ludmila Prokunina-Olsson
Publikováno v:
Diagnostic Microbiology and Infectious Disease. 92:34-36
In direct acting antiviral (DAA)-treated HCV genotype 1, the sustained virologic response rate with the ∆G/∆G genotype of IFNL4 rs368234815 (86.8%) was significantly lower than with ∆G/TT (95.9%, P = 0.03) or TT/TT (98.6%, P = 0.01). The SVR od
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c89ddc384e86fa8fb14e854a7b531709
https://doi.org/10.1016/j.diagmicrobio.2018.04.004
https://doi.org/10.1016/j.diagmicrobio.2018.04.004
Publikováno v:
Journal of viral hepatitis. 26(8)
Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) provides a needed hepatitis C virus (HCV) antiviral option for direct-acting antiviral (DAA)-experienced patients. We evaluated the effectiveness of SOF/VEL/VOX for 12 weeks in DAA-experienced patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e900bf6789bf32d93997c34db82cbf3
https://pubmed.ncbi.nlm.nih.gov/31012179
https://pubmed.ncbi.nlm.nih.gov/31012179
Publikováno v:
Alimentary Pharmacology & Therapeutics. 44:400-410
Real-world data are needed to inform hepatitis C virus (HCV) treatment decisions.To assess the comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin (LDV/SOF ± RBV) vs. ombitasvir/paritaprevir/ritonavir + dasabuvir (OPrD) ± RBV in genotyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d602fa0fa130c25d6f75871f1af89bd
https://doi.org/10.1111/apt.13696
https://doi.org/10.1111/apt.13696
Publikováno v:
Hepatology. 64:405-414
Real-world effectiveness data are needed to inform hepatitis C virus (HCV) treatment decisions. The uptake of ledipasvir/sofosbuvir (LDV/SOF) regimens across health care settings has been rapid, but variations often occur in clinical practice. The ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab3511a356c524663dc8722fc9eae1fe
https://doi.org/10.1002/hep.28625
https://doi.org/10.1002/hep.28625
Publikováno v:
Journal of hepatology. 70(1)
Background & Aim Understanding the real-world effectiveness of all-oral hepatitis C virus (HCV) regimens informs treatment decisions. We evaluated the effectiveness of daclatasvir + sofosbuvir ± ribavirin (DCV + SOF ± RBV) and velpatasvir/sofosbuvi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3435ccf3e63a4dfb1cd26f2e84307e
https://pubmed.ncbi.nlm.nih.gov/30266283
https://pubmed.ncbi.nlm.nih.gov/30266283